Literature DB >> 7746468

Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron.

M Tanaka1, A Sotomatsu, T Yoshida, S Hirai.   

Abstract

Membrane lipid peroxidation has been suggested to participate in the nigral degeneration of Parkinson's disease. In the present study, we demonstrate that bromocriptine inhibits lipid peroxidation in phospholipid liposomes induced by dopa and iron complexes. Because this lipid peroxidation is not mediated by active oxygen species, antioxidant properties of bromocriptine do not seem to be derived from radical scavenging effects in our experimental conditions. Bromocriptine had no scavenging effect on superoxide produced by hypoxanthine-xanthine oxidase when determined by the chemiluminescence assay using MCLA, a Cypridina luciferin analog, as a probe.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7746468     DOI: 10.1016/0304-3940(94)11128-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

3.  Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.

Authors:  K Tanaka; I Miyazaki; N Fujita; M E Haque; M Asanuma; N Ogawa
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

Review 4.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 5.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

6.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.